Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris.
Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022 04; 20(4):520-521.